January 19, 2021
car

Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine

Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced the publication in Nature Medicine of interim findings from its ongoing phase 1 GINAKIT2 clinical trial collaboration with Baylor College of Medicine and Texas Children’s Hospital, in high risk relapsed refractory (R/R) patients with neuroblastoma, a form of childhood cancer.

The interim results demonstrated that expressing the CAR with interlukin-15 (IL-15), a natural protein that supports NKT survival, enhanced the tumor-fighting capabilities and in vivo persistence of autologous NKT cells. Two of three patients studied showed tumor reduction following CAR-NKT infusion: one classified as stable disease and the other as a partial response. Imaging revealed a dramatic reduction in the size and metabolic activity of bone metastases in the patient with the partial response. CAR-NKT cells demonstrated a favorable safety profile and localized to the site of the

Read More
car

Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy

  • Allogeneic “off-the-shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome many of the challenges of current autologous CAR-T therapies

  • The CAR-NKT cell platform has tumor-homing properties and is unlikely to cause GvHD

  • Phase 1 ANCHOR clinical study will enroll adult patients with relapsed/refractory (R/R) CD19 positive malignancies

Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of hematological and solid malignancies, today announced the treatment of the first patients in its ANCHOR phase 1 study of KUR-502, an allogeneic CAR-NKT therapy.

“This is an important day, as the initiation and dosing of the first patients in the ANCHOR phase 1 clinical study marks the first time that patients have been treated with an allogeneic engineered CAR-NKT cell therapy,” said Dr. Carlos Ramos, Principal Investigator of the ANCHOR study, Professor of Medicine in the Center for Cell and Gene Therapy (CAGT) at

Read More

Ballard Expanding MEA Production Capacity 6x to Meet Expected Growth in Fuel Cell Electric Vehicle Demand

VANCOUVER, BC, Sept. 28, 2020 /PRNewswire/ – Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) today announced the company is expanding manufacturing capacity for production of its proprietary membrane electrode assemblies, or MEAs – a critical component of every fuel cell – 6x by early 2021 at its headquarter facility in Vancouver. The upgraded capacity for production of 6 million MEAs annually, equivalent to approximately 1.66 Gigawatts of product, will make Ballard’s Vancouver facility the largest fuel cell MEA production operation globally for commercial vehicles. Details of the expansion plan will be reviewed at Ballard’s virtual “Investor and Analyst Day 2020” event being held on September 29th, with further event details available here.

Ballard Power Systems (CNW Group/Ballard Power Systems Inc.)
Ballard Power Systems (CNW Group/Ballard Power Systems Inc.)

“We embarked on a strategic investment to expand MEA manufacturing capacity approximately 18-months ago in preparation for expected growth in the demand for fuel cell engines

Read More